Anavex Life Sciences Corp. (AVXL)
1.82
-0.07
(-3.70%)
USD |
NASDAQ |
Oct 02, 16:00
1.815
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Cash from Operations (Quarterly) : -9.096M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.096M |
| March 31, 2026 | -4.44M |
| December 31, 2025 | -7.151M |
| September 30, 2025 | -8.604M |
| June 30, 2025 | -12.46M |
| March 31, 2025 | -5.856M |
| December 31, 2024 | -12.12M |
| September 30, 2024 | -6.658M |
| June 30, 2024 | -5.18M |
| March 31, 2024 | -11.66M |
| December 31, 2023 | -7.318M |
| September 30, 2023 | -5.850M |
| June 30, 2023 | -7.652M |
| March 31, 2023 | -8.489M |
| December 31, 2022 | -5.794M |
| September 30, 2022 | -4.044M |
| June 30, 2022 | -7.054M |
| March 31, 2022 | -9.640M |
| December 31, 2021 | -3.501M |
| September 30, 2021 | -7.674M |
| June 30, 2021 | -7.521M |
| March 31, 2021 | -7.317M |
| December 31, 2020 | -7.871M |
| September 30, 2020 | -6.230M |
| June 30, 2020 | -4.069M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.263M |
| December 31, 2019 | -5.725M |
| September 30, 2019 | -2.534M |
| June 30, 2019 | -7.501M |
| March 31, 2019 | -4.332M |
| December 31, 2018 | -4.210M |
| September 30, 2018 | -4.053M |
| June 30, 2018 | -2.088M |
| March 31, 2018 | -2.821M |
| December 31, 2017 | -3.620M |
| September 30, 2017 | -2.192M |
| June 30, 2017 | -2.974M |
| March 31, 2017 | -0.6977M |
| December 31, 2016 | -3.154M |
| September 30, 2016 | -1.863M |
| June 30, 2016 | -2.224M |
| March 31, 2016 | -1.903M |
| December 31, 2015 | -3.247M |
| September 30, 2015 | -1.433M |
| June 30, 2015 | -1.430M |
| March 31, 2015 | -0.6703M |
| December 31, 2014 | -0.6931M |
| September 30, 2014 | -0.9169M |
| June 30, 2014 | -0.96M |
| March 31, 2014 | -0.3475M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Anixa Biosciences, Inc. | -1.77M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -29.29M |
| Free Cash Flow Per Share (Quarterly) | -0.0979 |
| Free Cash Flow to Equity (Quarterly) | -9.096M |
| Free Cash Flow to Firm (Quarterly) | -9.096M |
| Free Cash Flow Yield | -17.86% |